Author: Lauran Neergaard
-
Brain fog and other long COVID symptoms are the focus of new small treatment studies
WASHINGTON (AP) — The National Institutes of Health is beginning a handful of studies to test possible treatments for long COVID, an anxiously awaited step in U.S. efforts against the mysterious condition that afflicts millions. Monday’s announcement from the NIH’s $1.15 billion RECOVER project comes amid frustration from patients who’ve struggled for months or even…
-
New data: experimental drug slows Alzheimer’s
WASHINGTON • An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening — but the anxiously awaited new data leaves unclear how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner Biogen had announced this fall that the drug lecanemab appeared to work, a badly needed bright spot…
-
FDA advisers back Novavax COVID shots as 4th U.S. option
WASHINGTON • American adults who haven’t yet gotten vaccinated against COVID-19 might soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot. Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation’s fourth coronavirus shot for…
-
Pfizer COVID-19 shot expanded to U.S. children as young as 12
COVID-19 vaccines finally are headed for more kids as U.S. regulators on Monday expanded use of Pfizer’s shot to those as young as 12, sparking a race to protect middle and high school students before they head back to class in the fall. Shots could begin as soon as a federal vaccine advisory committee issues…
-
2nd COVID-19 vaccine set for OK in US with panel endorsement
WASHINGTON (AP) — A government advisory panel endorsed a second COVID-19 vaccine Thursday, paving the way for the shot to be added to the U.S. vaccination campaign. The Food and Drug Administration is expected to follow the recommendation for the vaccine from Moderna and the National Institutes of Health. The FDA advisers, in a 20-0…
-
2nd virus vaccine shows striking success in U.S. tests
A second experimental COVID-19 vaccine — this one from Moderna Inc. — yielded extraordinarily strong early results Monday, another badly needed dose of hope as the pandemic enters a terrible new phase. Moderna said its vaccine appears to be 94.5% effective, according to preliminary data from an ongoing study. A week ago, competitor Pfizer Inc.…
-
Experimental app might spot drug overdoses in time to help
WASHINGTON • Too often people die of an opioid overdose because no one’s around to notice they’re in trouble. Now scientists are creating a smartphone app that beams sound waves to measure breathing — and summon help if it stops. The app is still experimental. But in a novel test, the “Second Chance” app detected…
-
NIH ends alcohol study, citing funding, credibility problems
Facebook Twitter WhatsApp SMS Email Print Copy article link Save Facebook Twitter WhatsApp SMS Email Print Copy article link Save WASHINGTON — The U.S. government is shutting down a study that was supposed to show if a single drink a day could prevent heart attacks, saying ethical problems with how the research was planned and…
-
Injured U.S. military veteran gets world’s first penis and scrotum transplant
WASHINGTON — A veteran who lost his genitals from a blast in Afghanistan has received the world’s most extensive penis transplant, and doctors said Monday he is recovering well and expected to leave the hospital this week. Saying they wanted to address “an unspoken injury of war,” Johns Hopkins University surgeons rebuilt the man’s entire…
-
Scientists tune into brain to uncover music’s healing power
WASHINGTON — Like a friendly Pied Piper, the violinist keeps up a toe-tapping beat as dancers weave through busy hospital hallways and into the chemotherapy unit, patients looking up in surprised delight. Upstairs, a cellist strums an Irish folk tune for a patient in intensive care. Music increasingly is becoming a part of patient care…